Drug Profile
ACAT inhibitor
Latest Information Update: 02 Aug 2017
Price :
$50
*
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acne
Most Recent Events
- 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
- 02 Dec 2011 Medicis Pharmaceutical Corporation acquires pharmaceuticals assets of Graceway Pharmaceuticals
- 30 Sep 2011 No development reported - Phase-II for Acne in USA (unspecified route)